3 Medical Device Stocks Giving Investors a Different Healthcare Play

When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers . Medical device companies operate within a unique ecosystem and are often easy to overlook. The fact that these firms have unique business models, revenue drivers, and innovation cycles may make them appealing as a supplement—or even an alternative—to better-known corners of the health care space. Investors seeking the advantages of companies that don't depend on the approval of blockbuster drugs, can more easily make incremental innovations, or can derive revenue from recurring procedures, may want to consider the companies below. These and other similar firms stand to benefit from growing specialized demand for procedures such as spine surgery, sleep apnea treatment, and stroke treatment.

Globus Medical, Inc. NYSE: GMED is an $11-billion firm designing and building implantable devices and surgical instruments used to treat spinal disorders. The firm has been quietly thriving thanks to strong organic revenue growth and margin improvements: in Q1 2026 , for instance, revenue grew by 27% year over year (YOY) to nearly $760 million and earnings per share (EPS) climbed to $1.12 from 68 cents. Both of these figures were solidly above analyst expectations. Management credits the growth to improving market share, operational discipline, stronger free cash flow, and the introduction of dozens of new products. The company's U.S. business in particular is thriving, having seen three consecutive quarters of at least 10% growth, but its international segment and enabling technologies business are also growing. The company's products are widely favored and gaining additional traction thanks to Globus' strong sales approach, and it continues to receive new clearances from the FDA to expand its lineup. This has allowed the firm to raise its full-year EPS guidance by 30 cents to a range of $4.70-$4.80. Despite these positive attributes, shares of GMED have slumped by about 7% year to date (YTD), though analysts expect a reversal and upside potential of nearly 29% . More than two-thirds of the 16 ratings for GMED are Buys.

Nearly a third of U.S. adults over the age of 20 have obstructive sleep apnea (OSA), giving Inspire Medical Systems Inc. NYSE: INSP more than 80 million potential domestic customers. The company makes implantable neurostimulation devices to treat OSA. These devices are rapidly becoming a popular alternative to traditional continuous positive airway pressure (CPAP) options. Still, INSP shares have experienced a major sell-off so far this year, falling by 44% YTD. The likely reason for this is ...